Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,356Revenue (TTM) $M813Net Margin (%)-71.1Altman Z-Score0.3
Enterprise Value $M1,969EPS (TTM) $-8.1Operating Margin %-73.3Piotroski F-Score2
P/E(ttm)--Beneish M-Score-6.0Pre-tax Margin (%)-79.2Higher ROA y-yN
Price/Book2.610-y EBITDA Growth Rate %--Quick Ratio1.2Cash flow > EarningsY
Price/Sales1.65-y EBITDA Growth Rate %--Current Ratio1.8Lower Leverage y-yN
Price/Free Cash Flow23.1y-y EBITDA Growth Rate %-402.5ROA % (ttm)-31.4Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-78.8Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M74.3ROIC % (ttm)-42.3Gross Margin Increase y-yN

Gurus Latest Trades with IPXL

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
Current Price Change from Average Comment Current Shares

IPXL is held by these investors:

IPXL: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
NESTOR MICHAELPresident, Impax Specialty 2017-05-31Sell1,130$1533view
NESTOR MICHAELPresident, Impax Specialty 2017-05-17Sell857$16.4821.06view
NESTOR MICHAELPresident, Impax Specialty 2017-05-12Sell700$17.1116.6view
BENET LESLIE ZDirector 2016-08-15Sell10,092$22.81-12.54view
SCHLOSSBERG MARK ASVP and General Counsel 2015-09-11Sell7,457$43.3-53.93view
NESTOR MICHAELPresident, Impax Pharm. 2015-09-10Sell5,000$43.56-54.2view
FLEMING NIGELDirector 2015-08-31Sell29,166$41.02-51.37view
MARKBREITER MICHAELDirector 2015-08-31Sell28,000$41.7-52.16view
BENET LESLIE ZDirector 2015-08-31Sell20,000$40.92-51.25view
SCHLOSSBERG MARK ASVP and General Counsel 2015-08-27Sell4,649$43.41-54.04view

Quarterly/Annual Reports about IPXL:

News about IPXL:

Articles On GuruFocus.com
Impax to Report Third Quarter 2017 Results on November 9, 2017 Oct 03 2017 
Impax to Present at the Cantor Fitzgerald Global Healthcare Conference Sep 19 2017 
Impax to Present at the Morgan Stanley 15th Annual Global Healthcare Conference Sep 05 2017 
Impax Announces Settlement of Contract Litigation on Opana® ER (Oxymorphone Hydrochloride) CII Exte Aug 07 2017 
Impax Announces FDA Approval of its AB Rated Generic Concerta® (Methylphenidate Hydrochloride) Exte Jul 17 2017 
Impax to Present at the Goldman Sachs 38th Annual Global Healthcare Conference Jun 08 2017 
Impax to Present at the Bank of America Merrill Lynch Healthcare Conference May 11 2017 
Impax Announces FDA Approval and Launch of a Generic Version of Vytorin® (Ezetimibe/Simvastatin Tab Apr 26 2017 
Impax to Present Data on Rytary® (Carbidopa and Levodopa) Extended-Release Capsules, Zomig® (Zolmi Apr 21 2017 
Impax to Report First Quarter 2017 Results on May 10, 2017 Apr 06 2017 
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat